Sydney cancer immunotherapy research company, Imugene has presented positive vaccine trial results at the Annual American Association for Cancer Research.
The results were released after a trial period on a genetically identical mouse-model subject with HER-2+ breast cancer.
B-cell cancer growth was inhibited in the test subject after implementation of the newly developed mimitope programmed cell death protein (PD-1).
The PD-1 elicited an antibody response in the mouse that inhibited growth of the cancer tumor.
Imugene collaborated with the Medical University of Vienna at the Annual American during the trial tests.
Please read the announcement attached.
More From The Market Online
Breaking barriers in cancer treatment: Race Oncology pioneers a new era with bisantrene
Race Oncology (ASX:RAC) has announced positive results in killing cancer cells in combination with the drug…
- Jonathon Davidson
- 2 mins
- 14 May 2024 09:56 (AEST)
Optiscan agreement with Mayo Clinic aims to expedite robotic surgery
Optiscan Imaging is parterning with Mayo Clinic to develop a digital confocal laser endomicroscopic imaging system
- Fouad Haidar
- 1 min
- 13 May 2024 14:10 (AEST)
NDC BidCo acquires all of Pacific Smiles Group
Pacific Smiles Group (ASX:PSQ) has entered into an agreement with NDC BidCo Pty, to be fully…
- Fouad Haidar
- 1 min
- 13 May 2024 12:19 (AEST)
Family tracking app Life360 eyeing a US IPO as profitability approaches
Family tracking app developer Life360 announced on Friday that it is applying for a US IPO…
- Jonathon Davidson
- 2 mins
- 10 May 2024 12:15 (AEST)